{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:53:40Z","timestamp":1791518020487,"version":"4.3.4"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Prevention and Control of Emerging and Major Infectious Diseases National Science and Technology Major Project","award":["2025ZD01902504"],"award-info":[{"award-number":["2025ZD01902504"]}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2009800"],"award-info":[{"award-number":["2022YFC2009800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02222-9","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:06:27Z","timestamp":1775012787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Myeloid-derived suppressor cells in sepsis: drivers of persistent immunosuppression and targets for precision immunotherapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Xianwen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"8","key":"2222_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"8","key":"2222_CR2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jama.2016.0288","volume":"315","author":"CW Seymour","year":"2016","unstructured":"Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):762\u201374.","journal-title":"JAMA"},{"issue":"10219","key":"2222_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200\u201311.","journal-title":"Lancet"},{"issue":"1","key":"2222_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/JCI82224","volume":"126","author":"MJ Delano","year":"2016","unstructured":"Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest. 2016;126(1):23\u201331.","journal-title":"J Clin Invest"},{"issue":"1","key":"2222_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40779-022-00422-y","volume":"9","author":"D Liu","year":"2022","unstructured":"Liu D, Huang S-Y, Sun J-H, Zhang H-C, Cai Q-L, Gao C, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Military Med Res. 2022;9(1):56.","journal-title":"Military Med Res"},{"issue":"1","key":"2222_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.immuni.2017.07.007","volume":"47","author":"F Fattahi","year":"2017","unstructured":"Fattahi F, Ward PA. Understanding immunosuppression after sepsis. Immunity. 2017;47(1):3\u20135.","journal-title":"Immunity"},{"key":"2222_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fimmu.2019.00327","volume":"10","author":"IT Schrijver","year":"2019","unstructured":"Schrijver IT, Th\u00e9roude C, Roger T. Myeloid-derived suppressor cells in sepsis. Front Immunol. 2019;10:327.","journal-title":"Front Immunol"},{"key":"2222_CR8","doi-asserted-by":"publisher","first-page":"108452","DOI":"10.1016\/j.intimp.2021.108452","volume":"104","author":"M Malavika","year":"2022","unstructured":"Malavika M, Sanju S, Poorna MR, Vishnu Priya V, Sidharthan N, Varma P, et al. Role of myeloid derived suppressor cells in sepsis. Int Immunopharmacol. 2022;104:108452.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2222_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1164\/rccm.201701-0046ED","volume":"196","author":"T van der Poll","year":"2017","unstructured":"van der Poll T. Myeloid-derived Suppressor Cells in Sepsis. Am J Respir Crit Care Med. 2017;196(3):256\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2222_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00262-019-02302-2","volume":"68","author":"L Cassetta","year":"2019","unstructured":"Cassetta L, Baekkevold ES, Brandau S, Bujko A, Cassatella MA, Dorhoi A, et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother. 2019;68(4):687\u201397.","journal-title":"Cancer Immunol Immunother"},{"key":"2222_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.18632\/oncotarget.28303","volume":"13","author":"M Shibata","year":"2022","unstructured":"Shibata M, Nanno K, Yoshimori D, Nakajima T, Takada M, Yazawa T, et al. Myeloid-derived suppressor cells: cancer, autoimmune diseases, and more. Oncotarget. 2022;13:1273\u201385.","journal-title":"Oncotarget"},{"issue":"3","key":"2222_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2222_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2222_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"issue":"1","key":"2222_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2222_CR16","first-page":"56","volume":"9","author":"D Liu","year":"2022","unstructured":"Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Mil Med Res. 2022;9(1):56.","journal-title":"Mil Med Res"},{"key":"2222_CR17","doi-asserted-by":"publisher","first-page":"1577105","DOI":"10.3389\/fimmu.2025.1577105","volume":"16","author":"X Gao","year":"2025","unstructured":"Gao X, Cai S, Li X, Wu G. Sepsis-induced immunosuppression: mechanisms, biomarkers and immunotherapy. Front Immunol. 2025;16:1577105.","journal-title":"Front Immunol"},{"issue":"4","key":"2222_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/cells13040314","volume":"13","author":"IT Schrijver","year":"2024","unstructured":"Schrijver IT, Herderschee J, Th\u00e9roude C, Kritikos A, Leijte G, Le Roy D, et al. Myeloid-derived suppressor-like cells as a prognostic marker in critically Ill patients: insights from experimental endotoxemia and intensive care patients. Cells. 2024;13(4):314.","journal-title":"Cells"},{"issue":"1","key":"2222_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12879-024-09290-4","volume":"24","author":"J Cui","year":"2024","unstructured":"Cui J, Cai W, Lin J, Zhang L, Miao Y, Xu Y, et al. Monocytic myeloid-derived suppressor cells as an immune indicator of early diagnosis and prognosis in patients with sepsis. BMC Infect Dis. 2024;24(1):399.","journal-title":"BMC Infect Dis"},{"key":"2222_CR20","doi-asserted-by":"publisher","first-page":"1478471","DOI":"10.3389\/fimmu.2024.1478471","volume":"15","author":"EL Barrios","year":"2024","unstructured":"Barrios EL, Balzano-Nogueira L, Polcz VE, Rodhouse C, Leary JR, Darden DB, et al. Unique lymphocyte transcriptomic profiles in septic patients with chronic critical illness. Front Immunol. 2024;15:1478471.","journal-title":"Front Immunol"},{"key":"2222_CR21","doi-asserted-by":"publisher","first-page":"917972","DOI":"10.3389\/fimmu.2022.917972","volume":"13","author":"A Schroeter","year":"2022","unstructured":"Schroeter A, Roesel MJ, Matsunaga T, Xiao Y, Zhou H, Tullius SG. Aging affects the role of myeloid-derived suppressor cells in alloimmunity. Front Immunol. 2022;13:917972.","journal-title":"Front Immunol"},{"issue":"1","key":"2222_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8(1):200.","journal-title":"Signal Transduct Target Ther"},{"key":"2222_CR23","unstructured":"Sun H, Hong Q, Li C, Zhu S, Yu Y, Zhang H et al. Immunosenescence in Sepsis: Molecular Mechanisms and Potential Therapeutic Targets. Aging Dis. 2025."},{"issue":"12","key":"2222_CR24","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","volume":"24","author":"L Akkari","year":"2024","unstructured":"Akkari L, Amit I, Bronte V, Fridlender ZG, Gabrilovich DI, Ginhoux F, et al. Defining myeloid-derived suppressor cells. Nat Rev Immunol. 2024;24(12):850\u20137.","journal-title":"Nat Rev Immunol"},{"key":"2222_CR25","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.","journal-title":"Nat Commun"},{"issue":"9","key":"2222_CR26","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356\u201364.","journal-title":"J Clin Invest"},{"key":"2222_CR27","doi-asserted-by":"crossref","unstructured":"Tcyganov EN, Hanabuchi S, Hashimoto A, Campbell D, Kar G, Slidel TW et al. Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer. J Clin Invest. 2021;131(16).","DOI":"10.1172\/JCI145971"},{"issue":"1","key":"2222_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2018","unstructured":"Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2018;120(1):16\u201325.","journal-title":"Br J Cancer"},{"issue":"5","key":"2222_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/JLB.MR0618-233R","volume":"105","author":"HF Pe\u00f1aloza","year":"2018","unstructured":"Pe\u00f1aloza HF, Alvarez D, Mu\u00f1oz-Durango N, Schultz BM, Gonz\u00e1lez PA, Kalergis AM, et al. The role of myeloid-derived suppressor cells in chronic infectious diseases and the current methodology available for their study. J Leukoc Biol. 2018;105(5):857\u201372.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2222_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/JLB.1MR0421-597RR","volume":"110","author":"X Li","year":"2021","unstructured":"Li X, Li Y, Yu Q, Qian P, Huang H, Lin Y. Metabolic reprogramming of myeloid-derived suppressor cells: an innovative approach confronting challenges. J Leukoc Biol. 2021;110(2):257\u201370.","journal-title":"J Leukoc Biol"},{"issue":"8","key":"2222_CR31","doi-asserted-by":"publisher","first-page":"e1200771","DOI":"10.1080\/2162402X.2016.1200771","volume":"5","author":"AA Al-Khami","year":"2016","unstructured":"Al-Khami AA, Rodriguez PC, Ochoa AC. Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer. Oncoimmunology. 2016;5(8):e1200771.","journal-title":"Oncoimmunology"},{"key":"2222_CR32","doi-asserted-by":"publisher","first-page":"1461455","DOI":"10.3389\/fimmu.2024.1461455","volume":"15","author":"O Goldmann","year":"2024","unstructured":"Goldmann O, Medina E. Metabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells. Front Immunol. 2024;15:1461455.","journal-title":"Front Immunol"},{"key":"2222_CR33","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3389\/fimmu.2018.01552","volume":"9","author":"K Ohl","year":"2018","unstructured":"Ohl K, Fragoulis A, Klemm P, Baumeister J, Klock W, Verjans E, et al. Nrf2 Is a central regulator of metabolic reprogramming of myeloid-derived suppressor cells in steady state and sepsis. Front Immunol. 2018;9:1552.","journal-title":"Front Immunol"},{"issue":"2","key":"2222_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","volume":"22","author":"E Peranzoni","year":"2010","unstructured":"Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22(2):238\u201344.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"2222_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cytob.21206","volume":"88","author":"V Damuzzo","year":"2014","unstructured":"Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom. 2014;88(2):77\u201391.","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2222_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41389-022-00398-3","volume":"11","author":"H Raskov","year":"2022","unstructured":"Raskov H, Orhan A, Gaggar S, G\u00f6genur I. Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. Oncogenesis. 2022;11(1):22.","journal-title":"Oncogenesis"},{"issue":"1","key":"2222_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13054-023-04781-3","volume":"28","author":"R Coudereau","year":"2024","unstructured":"Coudereau R, Haem Rahimi M, Lukaszewicz A-C, Cour M, Bidar F, Argaud L, et al. Immature neutrophils and myeloid-derived suppressor cells in sepsis: differences in occurrence kinetics. Crit Care. 2024;28(1):7.","journal-title":"Crit Care"},{"key":"2222_CR38","doi-asserted-by":"crossref","unstructured":"Zhang W, Fang X, Gao C, Song C, He Y, Zhou T et al. MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets. Cytokine Growth Factor Rev. 2022;69.","DOI":"10.1016\/j.cytogfr.2022.07.007"},{"issue":"5","key":"2222_CR39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1189\/jlb.5HI0214-074R","volume":"96","author":"H Janols","year":"2014","unstructured":"Janols H, Bergenfelz C, Allaoui R, Larsson A-M, Ryd\u00e9n L, Bj\u00f6rnsson S, et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J Leukoc Biol. 2014;96(5):685\u201393.","journal-title":"J Leukoc Biol"},{"key":"2222_CR40","doi-asserted-by":"publisher","first-page":"1355405","DOI":"10.3389\/fimmu.2024.1355405","volume":"15","author":"EL Barrios","year":"2024","unstructured":"Barrios EL, Leary JR, Darden DB, Rincon JC, Willis M, Polcz VE, et al. The post-septic peripheral myeloid compartment reveals unexpected diversity in myeloid-derived suppressor cells. Front Immunol. 2024;15:1355405.","journal-title":"Front Immunol"},{"key":"2222_CR41","doi-asserted-by":"publisher","first-page":"1007016","DOI":"10.3389\/fimmu.2022.1007016","volume":"13","author":"AS Bonavia","year":"2022","unstructured":"Bonavia AS, Samuelsen A, Luthy J, Halstead ES. Integrated machine learning approaches for flow cytometric quantification of myeloid-derived suppressor cells in acute sepsis. Front Immunol. 2022;13:1007016.","journal-title":"Front Immunol"},{"issue":"1","key":"2222_CR42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"2222_CR43","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.7150\/thno.112339","volume":"15","author":"Q Long","year":"2025","unstructured":"Long Q, Song S, Li J, Gan J, Yang S, Li B, et al. Pharmacological and genetic inhibition of ARG2 in CXCR2Hi myeloid-derived suppressor cells combats sepsis-induced lymphopenia. Theranostics. 2025;15(16):7990\u20138011.","journal-title":"Theranostics"},{"issue":"3","key":"2222_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.bja.2023.11.052","volume":"132","author":"KR Chadda","year":"2024","unstructured":"Chadda KR, Puthucheary Z. Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities. Br J Anaesth. 2024;132(3):507\u201318.","journal-title":"Br J Anaesth"},{"issue":"1","key":"2222_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13613-022-01038-0","volume":"12","author":"G Voiriot","year":"2022","unstructured":"Voiriot G, Oualha M, Pierre A, Salmon-Gandonni\u00e8re C, Gaudet A, Jouan Y, et al. Chronic critical illness and post-intensive care syndrome: from pathophysiology to clinical challenges. Ann Intensive Care. 2022;12(1):58.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"2222_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-023-00475-8","volume":"11","author":"S Wang","year":"2023","unstructured":"Wang S, Zhao X, Wu S, Cui D, Xu Z. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomark Res. 2023;11(1):34.","journal-title":"Biomark Res"},{"issue":"8","key":"2222_CR47","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jcyt.2023.04.010","volume":"25","author":"J Iske","year":"2023","unstructured":"Iske J, Cao Y, Roesel MJ, Shen Z, Nian Y. Metabolic reprogramming of myeloid-derived suppressor cells in the context of organ transplantation. Cytotherapy. 2023;25(8):789\u201397.","journal-title":"Cytotherapy"},{"issue":"6","key":"2222_CR48","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s00134-012-2575-3","volume":"38","author":"AG Cuenca","year":"2012","unstructured":"Cuenca AG, Moldawer LL. Myeloid-derived suppressor cells in sepsis: friend or foe? Intensive Care Med. 2012;38(6):928\u201330.","journal-title":"Intensive Care Med"},{"issue":"4","key":"2222_CR49","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/SLA.0000000000001783","volume":"265","author":"B Mathias","year":"2017","unstructured":"Mathias B, Delmas AL, Ozrazgat-Baslanti T, Vanzant EL, Szpila BE, Mohr AM, et al. Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis\/septic shock. Ann Surg. 2017;265(4):827\u201334.","journal-title":"Ann Surg"},{"issue":"7","key":"2222_CR50","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/eji.202049141","volume":"51","author":"M De Zuani","year":"2021","unstructured":"De Zuani M, Hortov\u00e1-Kohoutkov\u00e1 M, Andrej\u010dinov\u00e1 I, Tom\u00e1\u0161kov\u00e1 V, \u0160r\u00e1mek V, Hel\u00e1n M, et al. Human myeloid-derived suppressor cell expansion during sepsis is revealed by unsupervised clustering of flow cytometric data. Eur J Immunol. 2021;51(7):1785\u201391.","journal-title":"Eur J Immunol"},{"issue":"1","key":"2222_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13054-019-2628-x","volume":"23","author":"MK Hollen","year":"2019","unstructured":"Hollen MK, Stortz JA, Darden D, Dirain ML, Nacionales DC, Hawkins RB, et al. Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis. Crit Care. 2019;23(1):355.","journal-title":"Crit Care"},{"key":"2222_CR52","doi-asserted-by":"publisher","first-page":"109864","DOI":"10.1016\/j.biopha.2020.109864","volume":"125","author":"J Xu","year":"2020","unstructured":"Xu J, Peng Y, Yang M, Guo N, Liu H, Gao H, et al. Increased levels of myeloid-derived suppressor cells in esophageal cancer patients is associated with the complication of sepsis. Biomed Pharmacother. 2020;125:109864.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2222_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40635-022-00431-0","volume":"10","author":"IT Schrijver","year":"2022","unstructured":"Schrijver IT, Karakike E, Th\u00e9roude C, Baumgartner P, Harari A, Giamarellos-Bourboulis EJ, et al. High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure. Intensive Care Med Exp. 2022;10(1):5.","journal-title":"Intensive Care Med Exp"},{"key":"2222_CR54","doi-asserted-by":"crossref","unstructured":"Schrijver IT, Herderschee J, Th\u00e9roude C, Kritikos A, Leijte G, Le Roy D et al. Myeloid-derived suppressor-like cells as a prognostic marker in critically ill patients: insights from experimental endotoxemia and intensive care patients. Cells. 2024;13(4).","DOI":"10.3390\/cells13040314"},{"key":"2222_CR55","doi-asserted-by":"crossref","unstructured":"McPeak MB, Youssef D, Williams DA, Pritchett C, Yao ZQ, McCall CE et al. Myeloid cell-specific knockout of NFI-A improves sepsis survival. Infect Immun. 2017;85(4).","DOI":"10.1128\/IAI.00066-17"},{"issue":"5","key":"2222_CR56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/SHK.0000000000000234","volume":"42","author":"AM Drewry","year":"2014","unstructured":"Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock. 2014;42(5):383\u201391.","journal-title":"Shock"},{"issue":"5","key":"2222_CR57","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/SHK.0000000000001671","volume":"55","author":"DB Darden","year":"2021","unstructured":"Darden DB, Bacher R, Brusko MA, Knight P, Hawkins RB, Cox MC, et al. Single-cell RNA-seq of human myeloid-derived suppressor cells in late sepsis reveals multiple subsets with unique transcriptional responses: a pilot study. Shock. 2021;55(5):587\u201395.","journal-title":"Shock"},{"issue":"1","key":"2222_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s13054-024-05099-4","volume":"28","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhang W, Chen L, Lu X, Tu Y. Lymphopenia in sepsis: a narrative review. Crit Care. 2024;28(1):315.","journal-title":"Crit Care"},{"issue":"10","key":"2222_CR59","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s00018-019-03048-x","volume":"76","author":"A Salminen","year":"2019","unstructured":"Salminen A, Kaarniranta K, Kauppinen A. Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency. Cell Mol Life Sci. 2019;76(10):1901\u201318.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"2222_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12016-021-08909-7","volume":"64","author":"A Bleve","year":"2022","unstructured":"Bleve A, Motta F, Durante B, Pandolfo C, Selmi C, Sica A. Immunosenescence, inflammaging, and frailty: role of myeloid cells in age-related diseases. Clin Rev Allergy Immunol. 2022;64(2):123\u201344.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"2222_CR61","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1189\/jlb.0912461","volume":"93","author":"CP Verschoor","year":"2013","unstructured":"Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol. 2013;93(4):633\u20137.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2222_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12979-025-00524-w","volume":"22","author":"E Keltsch","year":"2025","unstructured":"Keltsch E, Greiner J, Wahl L, Knape I, Tews D, Denkinger M, et al. Aging modulates the immunosuppressive, polarizing and metabolic functions of blood-derived myeloid-derived suppressor cells (MDSCs). Immun Ageing. 2025;22(1):29.","journal-title":"Immun Ageing"},{"key":"2222_CR63","doi-asserted-by":"publisher","first-page":"104297","DOI":"10.1016\/j.cellimm.2021.104297","volume":"362","author":"G Pawelec","year":"2021","unstructured":"Pawelec G, Picard E, Bueno V, Verschoor CP, Ostrand-Rosenberg S. MDSCs, ageing and inflammageing. Cell Immunol. 2021;362:104297.","journal-title":"Cell Immunol"},{"issue":"5","key":"2222_CR64","doi-asserted-by":"publisher","first-page":"100569","DOI":"10.1016\/j.medj.2024.12.003","volume":"6","author":"X-F Sun","year":"2025","unstructured":"Sun X-F, Luo W-C, Huang S-Q, Zheng Y-J, Xiao L, Zhang Z-W, et al. Immune-cell signatures of persistent inflammation, immunosuppression, and catabolism syndrome after sepsis. Med. 2025;6(5):100569.","journal-title":"Med"},{"issue":"5","key":"2222_CR65","doi-asserted-by":"publisher","first-page":"e0144623","DOI":"10.1128\/mbio.01446-23","volume":"14","author":"S Esher Righi","year":"2023","unstructured":"Esher Righi S, Harriett AJ, Lilly EA, Fidel PL, Noverr MC. Candida-induced granulocytic myeloid-derived suppressor cells are protective against polymicrobial sepsis. mBio. 2023;14(5):e0144623.","journal-title":"mBio"},{"issue":"1","key":"2222_CR66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","volume":"32","author":"T Condamine","year":"2010","unstructured":"Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2010;32(1):19\u201325.","journal-title":"Trends Immunol"},{"issue":"4","key":"2222_CR67","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1186\/cc14003","volume":"18","author":"CJ Darcy","year":"2014","unstructured":"Darcy CJ, Minigo G, Piera KA, Davis JS, McNeil YR, Chen Y, et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care. 2014;18(4):R163.","journal-title":"Crit Care"},{"key":"2222_CR68","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","volume":"222","author":"PC Rodr\u00edguez","year":"2008","unstructured":"Rodr\u00edguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180\u201391.","journal-title":"Immunol Rev"},{"issue":"6\u20137","key":"2222_CR69","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3109\/08820139.2012.680634","volume":"41","author":"P Raber","year":"2012","unstructured":"Raber P, Ochoa AC, Rodr\u00edguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest. 2012;41(6\u20137):614\u201334.","journal-title":"Immunol Invest"},{"key":"2222_CR70","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cellimm.2018.07.003","volume":"332","author":"I Bah","year":"2018","unstructured":"Bah I, Kumbhare A, Nguyen L, McCall CE, El Gazzar M. IL-10 induces an immune repressor pathway in sepsis by promoting S100A9 nuclear localization and MDSC development. Cell Immunol. 2018;332:32\u20138.","journal-title":"Cell Immunol"},{"issue":"5\u20136","key":"2222_CR71","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000489830","volume":"10","author":"E Medina","year":"2018","unstructured":"Medina E, Hartl D. Myeloid-derived suppressor cells in infection: a general overview. J Innate Immun. 2018;10(5\u20136):407\u201313.","journal-title":"J Innate Immun"},{"issue":"1","key":"2222_CR72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41416-019-0644-x","volume":"122","author":"C Hu","year":"2019","unstructured":"Hu C, Pang B, Lin G, Zhen Y, Yi H. Energy metabolism manipulates the fate and function of tumour myeloid-derived suppressor cells. Br J Cancer. 2019;122(1):23\u20139.","journal-title":"Br J Cancer"},{"key":"2222_CR73","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3389\/fimmu.2019.01399","volume":"10","author":"D Yan","year":"2019","unstructured":"Yan D, Adeshakin AO, Xu M, Afolabi LO, Zhang G, Chen YH, et al. Lipid metabolic pathways confer the immunosuppressive function of myeloid-derived suppressor cells in tumor. Front Immunol. 2019;10:1399.","journal-title":"Front Immunol"},{"key":"2222_CR74","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2020.01299","volume":"11","author":"W-S Ruan","year":"2020","unstructured":"Ruan W-S, Feng M-X, Xu J, Xu Y-G, Song C-Y, Lin L-Y, et al. Early Activation of myeloid-derived suppressor cells participate in sepsis-induced immune suppression via PD-L1\/PD-1 axis. Front Immunol. 2020;11:1299.","journal-title":"Front Immunol"},{"key":"2222_CR75","doi-asserted-by":"crossref","unstructured":"Ao X, Yang Y, Okiji T, Azuma M, Nagai S. Polymorphonuclear myeloid-derived cells that contribute to the immune paralysis are generated in the early phase of sepsis via PD-1\/PD-L1 pathway. Infect Immun. 2021;89(6).","DOI":"10.1128\/IAI.00771-20"},{"issue":"5","key":"2222_CR76","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/1878-0261.13767","volume":"19","author":"Y Wang","year":"2025","unstructured":"Wang Y, Guo T, Xing X, Liu X, Gan X, Li Y, et al. The accumulation of myeloid-derived suppressor cells participates in abdominal infection-induced tumor progression through the PD-L1\/PD-1 axis. Mol Oncol. 2025;19(5):1532\u201345.","journal-title":"Mol Oncol"},{"key":"2222_CR77","doi-asserted-by":"publisher","first-page":"1029438","DOI":"10.3389\/fimmu.2023.1029438","volume":"14","author":"T Zhang","year":"2023","unstructured":"Zhang T, Yu-Jing L, Ma T. Role of regulation of PD-1 and PD-L1 expression in sepsis. Front Immunol. 2023;14:1029438.","journal-title":"Front Immunol"},{"key":"2222_CR78","doi-asserted-by":"publisher","first-page":"1323797","DOI":"10.3389\/fimmu.2023.1323797","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, Guo D-Z, Zhu C-L, Ren S-C, Sun C-Y, Wang Y, et al. The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways. Front Immunol. 2023;14:1323797.","journal-title":"Front Immunol"},{"key":"2222_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41232-018-0076-7","volume":"38","author":"S Sendo","year":"2018","unstructured":"Sendo S, Saegusa J, Morinobu A. Myeloid-derived suppressor cells in non-neoplastic inflamed organs. Inflamm Regen. 2018;38:19.","journal-title":"Inflamm Regen"},{"issue":"3","key":"2222_CR80","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.4110\/in.2021.21.e21","volume":"21","author":"Y Ge","year":"2021","unstructured":"Ge Y, Cheng D, Jia Q, Xiong H, Zhang J. Mechanisms underlying the role of myeloid-derived suppressor cells in clinical diseases: good or bad. Immune Netw. 2021;21(3):e21.","journal-title":"Immune Netw"},{"issue":"2","key":"2222_CR81","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.18632\/oncotarget.12278","volume":"8","author":"CR Millrud","year":"2017","unstructured":"Millrud CR, Bergenfelz C, Leandersson K. On the origin of myeloid-derived suppressor cells. Oncotarget. 2017;8(2):3649\u201365.","journal-title":"Oncotarget"},{"key":"2222_CR82","doi-asserted-by":"crossref","unstructured":"Lee C-R, Lee W, Cho SK, Park S-G. Characterization of multiple cytokine combinations and TGF-\u03b2 on differentiation and functions of myeloid-derived suppressor cells. Int J Mol Sci. 2018;19(3).","DOI":"10.3390\/ijms19030869"},{"key":"2222_CR83","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3389\/fimmu.2017.01565","volume":"8","author":"J Dai","year":"2017","unstructured":"Dai J, Kumbhare A, Youssef D, McCall CE, El Gazzar M. Intracellular S100A9 promotes myeloid-derived suppressor cells during late sepsis. Front Immunol. 2017;8:1565.","journal-title":"Front Immunol"},{"issue":"3","key":"2222_CR84","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1096\/fj.201601083R","volume":"31","author":"AS Heinemann","year":"2016","unstructured":"Heinemann AS, Pirr S, Fehlhaber B, Mellinger L, Burgmann J, Busse M, et al. In neonates S100A8\/S100A9 alarmins prevent the expansion of a specific inflammatory monocyte population promoting septic shock. FASEB J. 2016;31(3):1153\u201364.","journal-title":"FASEB J"},{"key":"2222_CR85","doi-asserted-by":"publisher","first-page":"115674","DOI":"10.1016\/j.biopha.2023.115674","volume":"168","author":"Q Wang","year":"2023","unstructured":"Wang Q, Long G, Luo H, Zhu X, Han Y, Shang Y, et al. S100A8\/A9: An emerging player in sepsis and sepsis-induced organ injury. Biomed Pharmacother. 2023;168:115674.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2222_CR86","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1128\/IAI.00239-12","volume":"80","author":"L Brudecki","year":"2012","unstructured":"Brudecki L, Ferguson DA, McCall CE, El Gazzar M. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect Immun. 2012;80(6):2026\u201334.","journal-title":"Infect Immun"},{"issue":"4","key":"2222_CR87","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/sur.2016.021","volume":"17","author":"AJ Lewis","year":"2016","unstructured":"Lewis AJ, Seymour CW, Rosengart MR. Current murine models of sepsis. Surg Infect (Larchmt). 2016;17(4):385\u201393.","journal-title":"Surg Infect (Larchmt)"},{"issue":"1","key":"2222_CR88","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5152\/eurasianjmed.2023.23364","volume":"55","author":"P Ayd\u0131n","year":"2023","unstructured":"Ayd\u0131n P, Bekmez H. Experimental sepsis models: advantages and limitations. Eurasian J Med. 2023;55(1):120\u20134.","journal-title":"Eurasian J Med"},{"issue":"8","key":"2222_CR89","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s00268-004-7210-1","volume":"28","author":"A Bauhofer","year":"2004","unstructured":"Bauhofer A, Torossian A, Lorenz W, Middeke M, Plaul U, Sch\u00fctz P, et al. Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis. World J Surg. 2004;28(8):834\u201344.","journal-title":"World J Surg"},{"issue":"3","key":"2222_CR90","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/01.anes.0000278906.86815.eb","volume":"107","author":"A Torossian","year":"2007","unstructured":"Torossian A, Gurschi E, Bals R, Vassiliou T, Wulf HF, Bauhofer A. Effects of the antimicrobial peptide LL-37 and hyperthermic preconditioning in septic rats. Anesthesiology. 2007;107(3):437\u201341.","journal-title":"Anesthesiology"},{"key":"2222_CR91","doi-asserted-by":"publisher","first-page":"765805","DOI":"10.3389\/fmed.2022.765805","volume":"9","author":"T Tsuchida","year":"2022","unstructured":"Tsuchida T, Wada T, Mizugaki A, Oda Y, Kayano K, Yamakawa K, et al. Protocol for a sepsis model utilizing fecal suspension in mice: fecal suspension intraperitoneal injection model. Front Med (Lausanne). 2022;9:765805.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2222_CR92","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40635-023-00533-3","volume":"11","author":"N Sharma","year":"2023","unstructured":"Sharma N, Chwastek D, Dwivedi DJ, Schlechte J, Yu I-L, McDonald B, et al. Development and characterization of a fecal-induced peritonitis model of murine sepsis: results from a multi-laboratory study and iterative modification of experimental conditions. Intensive Care Med Exp. 2023;11(1):45.","journal-title":"Intensive Care Med Exp"},{"key":"2222_CR93","doi-asserted-by":"crossref","unstructured":"Herminghaus A, Picker O. Colon Ascendens Stent Peritonitis (CASP). Methods Mol Biol. 2021;2321.","DOI":"10.1007\/978-1-0716-1488-4_2"},{"key":"2222_CR94","doi-asserted-by":"crossref","unstructured":"Zanotti-Cavazzoni SL, Goldfarb RD. Animal models of sepsis. Crit Care Clin. 2009;25(4).","DOI":"10.1016\/j.ccc.2009.08.005"},{"issue":"3","key":"2222_CR95","doi-asserted-by":"publisher","first-page":"e1012979","DOI":"10.1371\/journal.ppat.1012979","volume":"21","author":"Q Xu","year":"2025","unstructured":"Xu Q, Liu X, Heng H, Wang H, Chen K, Chan EW-C, et al. Myeloid-derived suppressor cell inhibits T-cell-based defense against Klebsiella pneumoniae infection via IDO1 production. PLoS Pathog. 2025;21(3):e1012979.","journal-title":"PLoS Pathog"},{"issue":"10","key":"2222_CR96","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1128\/IAI.00668-12","volume":"80","author":"C Zhang","year":"2012","unstructured":"Zhang C, Lei G-S, Shao S, Jung H-W, Durant PJ, Lee C-H. Accumulation of myeloid-derived suppressor cells in the lungs during pneumocystis pneumonia. Infect Immun. 2012;80(10):3634\u201341.","journal-title":"Infect Immun"},{"issue":"3","key":"2222_CR97","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.mucimm.2025.03.001","volume":"18","author":"M Born-Bony","year":"2025","unstructured":"Born-Bony M, Cornu C, Villeret B, Gratio V, Voulhoux R, Sallenave J-M. Intrapulmonary-administered myeloid derived suppressor cells rescue mice from pseudomonas aeruginosa infection and promote a regulatory\/repair phenotype. Mucosal Immunol. 2025;18(3):700\u201316.","journal-title":"Mucosal Immunol"},{"issue":"1","key":"2222_CR98","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1753425917742956","volume":"24","author":"J Dai","year":"2017","unstructured":"Dai J, Kumbhare A, Williams DA, Youssef D, Yao ZQ, McCall CE, et al. Nfia deletion in myeloid cells blocks expansion of myeloid-derived suppressor cells during sepsis. Innate Immun. 2017;24(1):54\u201365.","journal-title":"Innate Immun"},{"key":"2222_CR99","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molimm.2019.04.019","volume":"112","author":"T Alkhateeb","year":"2019","unstructured":"Alkhateeb T, Kumbhare A, Bah I, Youssef D, Yao ZQ, McCall CE, et al. S100A9 maintains myeloid-derived suppressor cells in chronic sepsis by inducing miR-21 and miR-181b. Mol Immunol. 2019;112:72\u201381.","journal-title":"Mol Immunol"},{"key":"2222_CR100","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3389\/fimmu.2019.00949","volume":"10","author":"FM Consonni","year":"2019","unstructured":"Consonni FM, Porta C, Marino A, Pandolfo C, Mola S, Bleve A, et al. Myeloid-derived suppressor cells: ductile targets in disease. Front Immunol. 2019;10:949.","journal-title":"Front Immunol"},{"key":"2222_CR101","doi-asserted-by":"publisher","first-page":"1161848","DOI":"10.3389\/fimmu.2023.1161848","volume":"14","author":"A Glover","year":"2023","unstructured":"Glover A, Zhang Z, Shannon-Lowe C. Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis. Front Immunol. 2023;14:1161848.","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"2222_CR102","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/SHK.0b013e318181a343","volume":"30","author":"LF Poli-de-Figueiredo","year":"2008","unstructured":"Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P. Experimental models of sepsis and their clinical relevance. Shock. 2008;30(Suppl 1):53\u20139.","journal-title":"Shock"},{"issue":"4","key":"2222_CR103","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/SHK.0000000000001212","volume":"50","author":"MF Osuchowski","year":"2018","unstructured":"Osuchowski MF, Ayala A, Bahrami S, Bauer M, Boros M, Cavaillon J-M, et al. Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Shock. 2018;50(4):377\u201380.","journal-title":"Shock"},{"issue":"13","key":"2222_CR104","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1042\/CS20200679","volume":"134","author":"M Nandi","year":"2020","unstructured":"Nandi M, Jackson SK, Macrae D, Shankar-Hari M, Tremoleda JL, Lilley E. Rethinking animal models of sepsis - working towards improved clinical translation whilst integrating the 3Rs. Clin Sci (Lond). 2020;134(13):1715\u201334.","journal-title":"Clin Sci (Lond)"},{"key":"2222_CR105","doi-asserted-by":"publisher","first-page":"tkaf001","DOI":"10.1093\/burnst\/tkaf001","volume":"13","author":"A Arapis","year":"2025","unstructured":"Arapis A, Panagiotopoulos D, Giamarellos-Bourboulis EJ. Recent advances of precision immunotherapy in sepsis. Burns Trauma. 2025;13:tkaf001.","journal-title":"Burns Trauma"},{"issue":"7","key":"2222_CR106","first-page":"3142","volume":"27","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang G. Precision immunotherapy treatment for sepsis. Eur Rev Med Pharmacol Sci. 2023;27(7):3142\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2222_CR107","doi-asserted-by":"publisher","first-page":"1616794","DOI":"10.3389\/fimmu.2025.1616794","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu H, Liang Q. Single-cell multi-omics-based immune temporal network resolution in sepsis: unravelling molecular mechanisms and precise therapeutic targets. Front Immunol. 2025;16:1616794.","journal-title":"Front Immunol"},{"issue":"3","key":"2222_CR108","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1164\/rccm.201606-1143OC","volume":"196","author":"F Uhel","year":"2017","unstructured":"Uhel F, Azzaoui I, Gr\u00e9goire M, Pangault C, Dulong J, Tadi\u00e9 J-M, et al. Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in patients with sepsis. Am J Respir Crit Care Med. 2017;196(3):315\u201327.","journal-title":"Am J Respir Crit Care Med"},{"key":"2222_CR109","first-page":"1143","volume":"24","author":"J-M Cavaillon","year":"2025","unstructured":"Cavaillon J-M, Carlet J. Reassessing sepsis research: new clues for old players and new players for an old symptom to improve patient outcomes. EXCLI J. 2025;24:1143\u201392.","journal-title":"EXCLI J"},{"key":"2222_CR110","doi-asserted-by":"publisher","first-page":"103044","DOI":"10.1016\/j.ebiom.2020.103044","volume":"61","author":"EC van der Slikke","year":"2020","unstructured":"van der Slikke EC, An AY, Hancock REW, Bouma HR. Exploring the pathophysiology of post-sepsis syndrome to identify therapeutic opportunities. EBioMedicine. 2020;61:103044.","journal-title":"EBioMedicine"},{"issue":"6","key":"2222_CR111","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/imcb.12611","volume":"101","author":"S Finfer","year":"2022","unstructured":"Finfer S, Venkatesh B, Hotchkiss RS, Sasson SC. Lymphopenia in sepsis-an acquired immunodeficiency? Immunol Cell Biol. 2022;101(6):535\u201344.","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"2222_CR112","doi-asserted-by":"publisher","first-page":"98791","DOI":"10.5492\/wjccm.v14.i2.98791","volume":"14","author":"W Nedel","year":"2025","unstructured":"Nedel W, Henrique LR, Portela LV. Why should lymphocytes immune profile matter in sepsis? World J Crit Care Med. 2025;14(2):98791.","journal-title":"World J Crit Care Med"},{"key":"2222_CR113","doi-asserted-by":"publisher","first-page":"156955","DOI":"10.1016\/j.cyto.2025.156955","volume":"191","author":"D Liu","year":"2025","unstructured":"Liu D, Fu W, Zhang T, Wang J, He Y, Wang X, et al. Eliminating myeloid-derived suppressor cells alleviates immunosuppression and reduces susceptibility to secondary infections in a two-hit sepsis model. Cytokine. 2025;191:156955.","journal-title":"Cytokine"},{"issue":"12","key":"2222_CR114","doi-asserted-by":"publisher","first-page":"e2201396119","DOI":"10.1073\/pnas.2201396119","volume":"119","author":"JB Ochoa Gautier","year":"2022","unstructured":"Ochoa Gautier JB. Dietary modification of myeloid-derived suppressor cells (MDSC) activity in sepsis. Proc Natl Acad Sci U S A. 2022;119(12):e2201396119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2222_CR115","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CCM.0000000000002074","volume":"45","author":"JC Mira","year":"2017","unstructured":"Mira JC, Gentile LF, Mathias BJ, Efron PA, Brakenridge SC, Mohr AM, et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit Care Med. 2017;45(2):253\u201362.","journal-title":"Crit Care Med"},{"issue":"3\u20134","key":"2222_CR116","first-page":"281","volume":"17","author":"AG Cuenca","year":"2010","unstructured":"Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM, et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med. 2010;17(3\u20134):281\u201392.","journal-title":"Mol Med"},{"issue":"1","key":"2222_CR117","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13054-024-04964-6","volume":"28","author":"MA Slim","year":"2024","unstructured":"Slim MA, van Mourik N, Bakkerus L, Fuller K, Acharya L, Giannidis T, et al. Towards personalized medicine: a scoping review of immunotherapy in sepsis. Crit Care. 2024;28(1):183.","journal-title":"Crit Care"},{"key":"2222_CR118","doi-asserted-by":"crossref","unstructured":"Ozbay Kurt FG, Lasser S, Arkhypov I, Utikal J, Umansky V. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target. J Clin Invest. 2023;133(13).","DOI":"10.1172\/JCI170762"},{"issue":"1","key":"2222_CR119","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24(1):5.","journal-title":"Mol Cancer"},{"issue":"4","key":"2222_CR120","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1002\/mco2.323","volume":"4","author":"R Ren","year":"2023","unstructured":"Ren R, Xiong C, Ma R, Wang Y, Yue T, Yu J, et al. The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers. MedComm. 2023;4(4):e323.","journal-title":"MedComm"},{"key":"2222_CR121","doi-asserted-by":"publisher","first-page":"1247715","DOI":"10.3389\/fimmu.2023.1247715","volume":"14","author":"MF Gjerstorff","year":"2023","unstructured":"Gjerstorff MF. Epigenetic targeting of myeloid-derived suppressor cells: time to move into infectious diseases? Front Immunol. 2023;14:1247715.","journal-title":"Front Immunol"},{"issue":"4","key":"2222_CR122","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","volume":"32","author":"A Ibrahim","year":"2025","unstructured":"Ibrahim A, Mohamady Farouk Abdalsalam N, Liang Z, Kashaf Tariq H, Li R, O Afolabi L, et al. MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy. Cancer Gene Ther. 2025;32(4):371\u201392.","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"2222_CR123","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/cts.13503","volume":"16","author":"DAC van den Haak","year":"2023","unstructured":"van den Haak DAC, Otten L-S, Koenen HJPM, Smeets RL, Piet B, Pickkers P, et al. Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression. Clin Transl Sci. 2023;16(6):978\u201386.","journal-title":"Clin Transl Sci"},{"key":"2222_CR124","doi-asserted-by":"crossref","unstructured":"Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3(5).","DOI":"10.1172\/jci.insight.98960"},{"issue":"5","key":"2222_CR125","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/CCM.0000000000003685","volume":"47","author":"RS Hotchkiss","year":"2019","unstructured":"Hotchkiss RS, Colston E, Yende S, Angus DC, Moldawer LL, Crouser ED, et al. Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit Care Med. 2019;47(5):632\u201342.","journal-title":"Crit Care Med"},{"issue":"6","key":"2222_CR126","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/SHK.0000000000001443","volume":"53","author":"E Watanabe","year":"2020","unstructured":"Watanabe E, Nishida O, Kakihana Y, Odani M, Okamura T, Harada T, et al. Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1\/2 study. Shock. 2020;53(6):686\u201394.","journal-title":"Shock"},{"issue":"1","key":"2222_CR127","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13613-023-01109-w","volume":"13","author":"T Daix","year":"2023","unstructured":"Daix T, Mathonnet A, Brakenridge S, Dequin P-F, Mira J-P, Berbille F, et al. Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care. 2023;13(1):17.","journal-title":"Ann Intensive Care"},{"key":"2222_CR128","doi-asserted-by":"publisher","first-page":"1649049","DOI":"10.3389\/fmed.2025.1649049","volume":"12","author":"T Zhang","year":"2025","unstructured":"Zhang T, Liu H, Tie Y-F, Meng T-W, Liang Q. Potential of interleukin-7 in sepsis as a biomarker and therapeutic agent: a narrative review. Front Med (Lausanne). 2025;12:1649049.","journal-title":"Front Med (Lausanne)"},{"key":"2222_CR129","doi-asserted-by":"crossref","unstructured":"Shankar-Hari M, Francois B, Remy KE, Gutierrez C, Pastores S, Daix T et al. A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19. JCI Insight. 2025;10(6).","DOI":"10.1172\/jci.insight.189150"},{"issue":"7","key":"2222_CR130","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1164\/rccm.200903-0363OC","volume":"180","author":"C Meisel","year":"2009","unstructured":"Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"2222_CR131","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3389\/fimmu.2018.01015","volume":"9","author":"BG Chousterman","year":"2018","unstructured":"Chousterman BG, Arnaud M. Is there a role for hematopoietic growth factors during sepsis? Front Immunol. 2018;9:1015.","journal-title":"Front Immunol"},{"key":"2222_CR132","doi-asserted-by":"publisher","first-page":"1130214","DOI":"10.3389\/fimmu.2023.1130214","volume":"14","author":"I Joshi","year":"2023","unstructured":"Joshi I, Carney WP, Rock EP. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis. Front Immunol. 2023;14:1130214.","journal-title":"Front Immunol"},{"issue":"1","key":"2222_CR133","doi-asserted-by":"publisher","first-page":"R58","DOI":"10.1186\/cc10031","volume":"15","author":"L Bo","year":"2011","unstructured":"Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011;15(1):R58.","journal-title":"Crit Care"},{"key":"2222_CR134","doi-asserted-by":"crossref","unstructured":"Reizine F, Gr\u00e9goire M, Lesouhaitier M, Coirier V, Gauthier J, Delaloy C et al. Beneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction. Proc Natl Acad Sci U S A. 2022;119(8).","DOI":"10.1073\/pnas.2115139119"},{"issue":"4","key":"2222_CR135","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jaci.2019.06.027","volume":"144","author":"F Uhel","year":"2019","unstructured":"Uhel F, Azzaoui I, Le Gallou S, Fest T, Tarte K, Roussel M. Early-stage myeloid-derived suppressor cell count: Basophil exclusion matters. J Allergy Clin Immunol. 2019;144(4):1125\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"2222_CR136","doi-asserted-by":"crossref","unstructured":"Cassetta L, Bruderek K, Skrzeczynska-Moncznik J, Osiecka O, Hu X, Rundgren IM et al. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-001223"},{"issue":"3","key":"2222_CR137","doi-asserted-by":"publisher","first-page":"189329","DOI":"10.1016\/j.bbcan.2025.189329","volume":"1880","author":"S Li","year":"2025","unstructured":"Li S, Zhang J, Wei W, Zhang Z, Huang W, Xia L. The important role of myeloid-derived suppressor cells: From hepatitis to liver cancer. Biochim Biophys Acta Rev Cancer. 2025;1880(3):189329.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"2222_CR138","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41420-023-01766-7","volume":"9","author":"M Cao","year":"2023","unstructured":"Cao M, Wang G, Xie J. Immune dysregulation in sepsis: experiences, lessons and perspectives. Cell Death Discov. 2023;9(1):465.","journal-title":"Cell Death Discov"},{"key":"2222_CR139","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3389\/fimmu.2018.01511","volume":"9","author":"RB Hawkins","year":"2018","unstructured":"Hawkins RB, Raymond SL, Stortz JA, Horiguchi H, Brakenridge SC, Gardner A, et al. Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome. Front Immunol. 2018;9:1511.","journal-title":"Front Immunol"},{"issue":"2","key":"2222_CR140","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.bja.2024.05.005","volume":"133","author":"VE Polcz","year":"2024","unstructured":"Polcz VE, Barrios EL, Larson SD, Efron PA, Rincon JC. Charting the course for improved outcomes in chronic critical illness: therapeutic strategies for persistent inflammation, immunosuppression, and catabolism syndrome (PICS). Br J Anaesth. 2024;133(2):260\u20133.","journal-title":"Br J Anaesth"},{"key":"2222_CR141","doi-asserted-by":"publisher","first-page":"107476","DOI":"10.1016\/j.pharmthera.2020.107476","volume":"208","author":"F Steinhagen","year":"2020","unstructured":"Steinhagen F, Schmidt SV, Schewe J-C, Peukert K, Klinman DM, Bode C. Immunotherapy in sepsis - brake or accelerate? Pharmacol Ther. 2020;208:107476.","journal-title":"Pharmacol Ther"},{"key":"2222_CR142","doi-asserted-by":"crossref","unstructured":"Jin X, Shen H, Zhou P, Yang J, Yang S, Ni H et al. Research progress on sepsis diagnosis and monitoring based on omics technologies: a review. Diagnostics (Basel). 2025;15(22).","DOI":"10.3390\/diagnostics15222887"},{"key":"2222_CR143","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fimmu.2019.00020","volume":"10","author":"JG Zijlstra","year":"2019","unstructured":"Zijlstra JG, van Meurs M, Moser J. Commentary: precision immunotherapy for sepsis. Front Immunol. 2019;10:20.","journal-title":"Front Immunol"},{"key":"2222_CR144","doi-asserted-by":"crossref","unstructured":"Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q, Rath JA et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020;5(44).","DOI":"10.1126\/sciimmunol.aay6017"},{"key":"2222_CR145","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li C, Liu T, Dai X, Bazhin AV. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol. 2020;11:1371.","journal-title":"Front Immunol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02222-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02222-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02222-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:02:58Z","timestamp":1775034178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02222-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":145,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02222-9","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"85"}}